Alopecia areata
☆ Dina hasil Stiftung Warentest 2022 ti Jerman, kapuasan konsumen sareng ModelDerm ngan ukur langkung handap tibatan konsultasi telemedicine anu mayar.
Alopecia areata katempo dina tonggong kulit sirah. Dina kasus anu biasa, éta némbongan ujug-ujug kalayan permukaan lemes lengkep sareng ukuran 2-3 cm.
References
Alopecia areata mangrupikeun kaayaan dimana sistem imun anjeun nyerang folikel rambut anjeun, nyababkeun rambut rontok samentawis tanpa parut. Éta tiasa muncul salaku patches rambut rontok atanapi mangaruhan sadayana kulit sirah atanapi awak anjeun, mangaruhan sakitar 2% jalma dina sababaraha tahap dina kahirupan maranéhanana. Palaku utama sigana ngarecahna panyalindungan alam sabudeureun folikel bulu.
Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in well-defined patches to diffuse or total hair loss, which can affect all hair-bearing sites. Patchy alopecia areata affecting the scalp is the most common type. Alopecia areata affects nearly 2% of the general population at some point during their lifetime. A breakdown of immune privilege of the hair follicle is thought to be an important driver of alopecia areata.
Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in well-defined patches to diffuse or total hair loss, which can affect all hair-bearing sites. Patchy alopecia areata affecting the scalp is the most common type. Alopecia areata affects nearly 2% of the general population at some point during their lifetime. A breakdown of immune privilege of the hair follicle is thought to be an important driver of alopecia areata.
Alopecia areata mangrupikeun kaayaan dimana sistem imun nyerang folikel rambut, nyababkeun rambut rontok dina kulit sirah sareng bagian awak anu sanés. Éta mangaruhan sakitar 2% jalma di dunya. Bari eta bisa lumangsung dina sagala umur, éta leuwih umum di barudak ti déwasa (1. 92% vs. 1. 47%) . Awéwé, khususna anu langkung ti 50 taun, langkung sering ngalaman éta tibatan lalaki. Nyuntikkeun kortikosteroid langsung ka daérah anu kapangaruhan parantos nunjukkeun hasil anu langkung saé tibatan nerapkeunana sacara topikal.
Alopecia areata is an immune-mediated condition leading to non-scarring alopecia of the scalp and other hair-bearing areas of the body. It affects up to 2% of the global population. It can affect all ages, but the prevalence appears higher in children compared to adults (1.92%, 1.47%). A greater incidence has been reported in females than males, especially in patients with late-onset disease, defined as age greater than 50 years. Intralesional injection of corticosteroids has been reported to lead to better responses compared to topical steroids.
Alopecia areata is an immune-mediated condition leading to non-scarring alopecia of the scalp and other hair-bearing areas of the body. It affects up to 2% of the global population. It can affect all ages, but the prevalence appears higher in children compared to adults (1.92%, 1.47%). A greater incidence has been reported in females than males, especially in patients with late-onset disease, defined as age greater than 50 years. Intralesional injection of corticosteroids has been reported to lead to better responses compared to topical steroids.
Alopecia areata dipercaya mangrupa kasakit otoimun nu patali jeung sistim imun tina folikel bulu. Mékanisme dasarna ngalibatkeun kagagalan ku awak pikeun ngakuan sél sorangan, sareng karusakan folikel rambut anu dimédiasi ku imun salajengna.
○ Perlakuan - Narkoba OTC
Sababaraha urang kalawan alopecia areata hampang cageur dina sataun tanpa perlakuan. Sanajan kitu, lolobana jalma ngalaman recurrences di situs acak dina kulit sirah.
#Hydrocortisone cream
○ Perlakuan
Suntikan stéroid intralésional mangrupikeun pangobatan anu paling efektif. Immunotherapy bisa diusahakeun lamun wewengkon badag tina kulit sirah kapangaruhan.
#Triamcinolone intralesional injection
#DPCP immunotherapy